Trial · NCT07908290
Shower Gel and Participant-Reported Post-Exercise Soreness in Regular Exercisers
NCT07908290, Not applicable, Recruiting, The Humanix
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Shower Gel and Participant-Reported Post-Exercise Soreness in Regular Exercisers. Trials, record NCT07908290. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07908290
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Shower Gel and Participant-Reported Post-Exercise Soreness in Regular Exercisers
- NCT number
- NCT07908290
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 100 participants, estimated
- Lead sponsor
- The Humanix
- Conditions
- Post-Exercise Recovery, Muscle Soreness
- Interventions
- Topical shower gel, Comparator
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Numerical Rating Scale (NRS) for muscle soreness | Baseline (pre-exercise), immediate post-exercise, 24 hours, 48 hours (primary endpoint), and 72 hours post-exercise. | Adjusted between-group mean difference in 0-10 perceived muscle soreness Numerical Rating Scale (NRS) at 48 hours post-exercise (measured after the second product application / before the third application). Evaluated via ANCOVA model adjusting for immediate post-exercise/pre-application soreness, sex, and age. Scale ranges from 0 (no soreness at all) to 10 (worst possible soreness), where lower scores represent a better outcome. |
| Secondary | User Application and Sensory Experience | 24 hours post-exercise. | Participant ratings of product dispensing ease, rinsing ease, texture, and skin feel. Evaluated on Numerical Rating Scale (NRS) 0-10 scales (0 = very difficult, 10 = very easy) and categorical checklists, where higher scores represent more favorable product experience. |
| Secondary | User Satisfaction and Enjoyment Descriptors (CATA Format) | 24 hours post-exercise. | Check-All-That-Apply (CATA) word frequency analysis evaluating emotional and sensory descriptors between independent treatment and comparator groups using Pearson's Chi-square or Fisher's exact tests. Analyzed as selection proportions (0 to 1) and risk differences, where higher selection frequency for positive attributes indicates a better outcome. |
| Secondary | Consumer Perception and Commercial Intent Scale | 24 and 72 hours post-exercise. | Participant ratings of overall satisfaction, likelihood of regular post-workout use, recommendation intent, and purchase intent. Evaluated on 0-10 NRS scales (0 = not at all, 10 = extremely), where higher scores represent higher satisfaction and commercial intent. |
| Secondary | Perceived Post-Exercise Recovery Rating | 24 hours, 48 hours, and 72 hours post-exercise. | Single-item perceived recovery rating evaluated on a 0-10 NRS scale (0 = very poorly recovered/extremely tired, 10 = very well recovered/highly energetic), where higher scores represent superior perceived recovery. |
| Secondary | Hooper Index Score for Recovery and Readiness | Baseline (pre-exercise), 24 hours, 48 hours, and 72 hours post-exercise. | Multi-item questionnaire tracking perceived fatigue, sleep quality, muscle soreness, and stress on 0-10 NRS scales. Fatigue, soreness, and stress are scored from 0 (best) to 10 (worst), while sleep quality is scored from 0 (very poor) to 10 (excellent). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07908290
GET https://conductscience.org/api/trials/v1/NCT07908290/registered